Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Boston Scientific Corporation

The Highest-Rated Healthcare Stock to Buy Now to Hedge Against Oil Price Shocks

Amid oil-driven volatility, investors lean on resilient sectors, with Boston Scientific Corporation now standing out as a steady defensive healthcare play.

Barchart · Mar 18

Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion.

Benzinga · Oct 23, 2025

Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy.

Benzinga · Aug 8, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Boston Scientific Stock: Is BSX Outperforming the Healthcare Sector?

Boston Scientific has recently outpaced the broader healthcare sector, with analysts maintaining a highly bullish outlook on its future performance.

Barchart · Mar 5, 2025

3 Medical Device Stocks Seeing Surge in Demand

From robotic surgery to smart diagnostics, the medical devices industry is transforming healthcare delivery. To capitalize on this trend, you might consider adding Boston Scientific Corp (BSX), Becton, Dickinson and Company (BDX), and The Cooper Companies (COO), which could boost your portfolio. Keep reading….

StockNews.com · Feb 21, 2025

Is Boston Scientific Stock Outperforming the Dow?

Boston Scientific has outperformed the Dow recently, and analysts are strongly optimistic about the stock’s prospects.

Barchart · Dec 3, 2024

3 Healthcare Stocks Benefiting From Aging Populations

The healthcare industry is thriving, owing to the growing healthcare expenditure and aging population. Given the industry’s tailwinds, fundamentally sound healthcare stocks AbbVie (ABBV), Boston Scientific (BSX), and CVS Health (CVS) could be solid buys. Keep Reading….

StockNews.com · Sep 11, 2024

Read news from The Economist, FT, and more,
with one subscription

3 'Strong Buy' Stocks to Grab Now for More Gains

For investors looking to add some high-potential stocks to their portfolio, here are three top-rated opportunities to consider now.

Barchart · Sep 5, 2024

3 MedTech Stocks Innovating Healthcare

MedTech’s bright future is fueled by rapid tech advancements and increasing demand for medical devices, implants, and precision treatments, driven by an aging population and rising global disease rates. Given this backdrop, adding strong MedTech stocks like Boston Scientific (BSX), Stryker (SYK), and Abbott (ABT) to one’s portfolio could be…

StockNews.com · Aug 20, 2024

3 Safe Haven Stocks to Own in an Unpredictable Market

Even though 2024 kicked off strong, recent macroeconomic uncertainties highlight the need for resilient investments. These three “safe haven” stocks are worth considering for hedging against the market downswings.

Barchart · Apr 17, 2024

4 Hyper-Growth Stocks That Could Soar

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

StockNews.com · May 24, 2023

Boston Scientific Buys Substantial Stake In Korean MedTech Player

Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures. The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. M.I.Tech offers HANAROSTENT technology, a…

Benzinga · Jun 15, 2022

Coverage From

People

Mike Matson

21 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.